Biotech
-
Getty Images
3 KRAS drugs to watch as the field expands
Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark on the space.
By Kelly Bilodeau • Sept. 15, 2026 -
howtogoto via Getty Images
Cancer still dominates pharma R&D. Obesity is gaining ground.
Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third of drugs target at least one rare disease.
By Alexandra Pecci • Sept. 11, 2026 -
Explore the Trendline➔
Getty Images
TrendlineEmerging biotech
After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.
By PharmaVoice staff -
Alamy
Merck builds around Keytruda; prediction markets raise new risks
Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.
By PharmaVoice Staff • Sept. 11, 2026 -
Getty Images
mRNA cancer vaccines’ biggest barriers to market
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
By Alexandra Pecci • Sept. 10, 2026 -
Getty Images
5 questions that could determine Alzheimer’s next chapter
“The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?
By Kelly Bilodeau • Sept. 9, 2026 -
Sarah Silbiger via Getty Images
FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.
By Kristin Jensen • Sept. 9, 2026 -
Justin Sullivan via Getty Images
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
By PharmaVoice Staff • Sept. 4, 2026 -
Joe Raedle via Getty Images
As measles outbreaks soar, where does drug R&D stand?
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up against a tense market environment.
By Alexandra Pecci • Sept. 4, 2026 -
Getty Images
The hidden scale-out problem behind CAR-T’s growth
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.
By Sy Mukherjee • Sept. 1, 2026 -
Getty Images
Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.
By Alexandra Pecci • Aug. 31, 2026 -
Permission granted by Argenx
Q&A // First 90 DaysA single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
By Meagan Parrish • Aug. 28, 2026 -
Getty Images
3 takeover targets in immunology
Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.
By Kelly Bilodeau • Aug. 26, 2026 -
Getty Images
Q&AIs AI finally proving its worth in drug R&D?
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?
By Kelly Bilodeau • Aug. 26, 2026 -
Getty Images
Q&ALegend’s interim CEO sees a shorter path to the next era of CAR-T
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
By Sy Mukherjee • Aug. 25, 2026 -
Permission granted by Tyra Biosciences
Tyra’s one-drug, three-indication bet nears its first phase 2 test
What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a blockbuster potential pipeline.
By Alexandra Pecci • Aug. 21, 2026 -
Getty Images
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod
A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower doses of its obesity pill.
By PharmaVoice Staff • Aug. 21, 2026 -
Getty Images
OpinionThe scientific research pharma leaders keep sharing — and why
Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, real-world evidence and trial design.
By Kelly Bilodeau • Aug. 20, 2026 -
Getty Images
FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
By Alexandra Pecci • Aug. 17, 2026 -
Sean Gallup / Staff via Getty Images via Getty Images
BioNTech’s oncology pivot comes with a new CEO
Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.
By Kelly Bilodeau • Aug. 14, 2026 -
Getty Images
Biotech initiatives pick up as more regions race to become hubs
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.
By Alexandra Pecci • Aug. 13, 2026 -
Permission granted by Image courtesy of Formation Bio
Profile // First 90 DaysFormation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’
Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
By Alexandra Pecci • Aug. 12, 2026 -
Getty Images
Did Novo’s phase 3 flop kill the inflammation hypothesis in heart disease?
While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.
By Kelly Bilodeau • Aug. 10, 2026 -
Getty Images
FDA allows unique endpoint in rare disease study
Global regulators are allowing the company to use hospitalization as the primary efficacy endpoint in its registration trial for a rare neuromuscular disorder.
By Alexandra Pecci • Aug. 5, 2026 -
Getty Images
Three potential takeover targets in psychedelics
Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.
By Kelly Bilodeau • Aug. 4, 2026 -
Getty Images
Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision
Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.
By PharmaVoice Staff • July 31, 2026
